Sientra

Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Siena Holdings, Inc. operates as a holding American company that manages and operates an assisted care facility through its subsidiary. The private company is located in the US and has subsidiaries in the United States.

Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process

Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

Sientra, Inc. (NASDAQ:SIEN ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Oliver Bennett - Chief Legal, Compliance and Corporate Development Officer Ron Menezes - President and Chief Executive Officer Denise Dajles - Chief Technical Officer Andy Schmidt - Chief Financial Officer Conference Call Participants Jordan Bernstein - Stifel Jeremy Pearlman - Maxim Group Operator Good afternoon and welcome to the Sientra Third Quarter 2023 Financial Results Conference Call. My name is Dave.

Sientra, Inc. (SIEN) Q3 2023 Earnings Call Transcript

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023.

Sientra Reports Third Quarter Financial and Operational Results

IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare Conference. As part of the conference, the company's management team will participate in a live fireside chat on Wednesday, November 15, 2023 at 8:00am EST / 5:00am PST.

Sientra to Present at the Stifel 2023 Healthcare Conference

IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023.

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook

Black Rifle Coffee

Celcuity

CompoSecure

RumbleON

Wheels Up Experience

VistaGen Therapeutics

The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.

The 7 Best Short-Squeeze Stocks to Buy Now: September 2023

Sientra (SIEN) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $2.90 per share a year ago.

Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates

Sientra, Inc. (NASDAQ:SIEN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Oliver Bennett - Chief Legal Compliance & Corporate Development Officer Ron Menezes - President & Chief Executive Officer Denise Dajles - Chief Technical Officer Andy Schmidt - Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group Jordan Bernstein - Stifel Alex Nowak - Craig-Hallum Group Operator Good afternoon and welcome to the Sientra Second Quarter 2023 Financial Results Conference Call. My name is Keith.

Sientra, Inc. (SIEN) Q2 2023 Earnings Call Transcript

Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement in operating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter that ended June 30, 2023.

Sientra Reports Record Second Quarter Financial and Operational Results

IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN)(“Sientra” or the “Company”), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023

IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees.

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023.

Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

After Sientra ( US:SIEN ) announced last week that the FDA had approved the company's tissue expander, the shares' put/call ratio remains very favorable this week, and the number of purchases of SIEN stock options held by investors surged on June 12, data from Fintel shows.

As Sientra Options Become Less Bullish This Week, Short Sellers Are Moving In

Shares of Sientra Inc. SIEN, +3.55% skyrocketed 82.3% toward a seven-month high on heavy volume to pace all premarket gainers Friday after the medical aesthetics company after the U.S. Food and Drug Administration granted 510(k)-clearance for its AlloX2 Pro Tissue Expander. Trading volume ballooned to 4.2 million shares, compared with the full-day average of about 328,900 shares.

Sientra stock rockets to pace premarket gainers after FDA clearance of tissue expander

Significant Milestone as the First, and Only, MRI-Compatible Tissue Expander Available on the US Market Continues Sientra's Leadership and Innovation in Breast Reconstruction IRVINE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510k-clearance for the Company's novel, patented1 AlloX2 Pro Tissue Expander.

Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander

Sientra (SIEN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Why Fast-paced Mover Sientra (SIEN) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sientra (SIEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Sientra (SIEN) Is Still a Bargain Stock

Continued Innovation Showcases Sientra's Leadership in Reconstruction Surgeries Continued Innovation Showcases Sientra's Leadership in Reconstruction Surgeries

Sientra Announces FDA-Clearance of Novel Portfinder™ Technology

Sientra, Inc. (NASDAQ:SIEN ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Oliver Bennett - Chief Legal Compliance and CDO Ron Menezes - President and CEO Andy Schmidt - Chief Financial Officer Denise Dajles - Chief Technical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Joe Federico - Stifel Anthony Vendetti - Maxim Group Operator Good afternoon, everybody. And welcome to Sientra's First Quarter 2023 Financial Results Conference Call.

Sientra, Inc. (SIEN) Q1 2023 Earnings Call Transcript

IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eleventh consecutive quarter of year-over-year growth, fueled by market outperformance  in reconstruction

Sientra Reports Record First Quarter 2023 Operational Results

IRVINE, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report First Quarter 2023 Financial Results on May 11, 2023

Sientra, Inc. (NASDAQ:SIEN ) Q4 2022 Results Conference Call March 30, 2023 4:00 PM ET Company Participants Oliver Bennett - General Counsel and Chief Compliance Officer Ron Menezes - President and CEO Andy Schmidt - CFO Lisa Rosas - SVP, Marketing Denise Dajles - SVP, Research and Development, Regulatory and Quality Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Jon Block - Stifel Anthony Vendetti - Maxim Group Operator Good day. And welcome to the Sientra Incorporated Fourth Quarter and Full Year 2022 Earnings Conference Call.

Sientra, Inc. (SIEN) Q4 2022 Earnings Call Transcript

Sientra (SIEN) delivered earnings and revenue surprises of -137.50% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sientra (SIEN) Reports Q4 Loss, Misses Revenue Estimates

Continued 2+ year trend of consecutive record quarterly growth; fastest growing brand in the US breast market

News for Sientra Stock (SIEN)